Abstract
Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Current Pharmaceutical Design
Title: Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Volume: 17 Issue: 14
Author(s): Sophia Achab and Yasser Khazaal
Affiliation:
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Abstract: Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Export Options
About this article
Cite this article as:
Achab Sophia and Khazaal Yasser, Psychopharmacological Treatment in Pathological Gambling: A Critical Review, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150774
DOI https://dx.doi.org/10.2174/138161211796150774 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Determination of Homocysteine in Human Saliva by Liquid Chromatography and Electrospray Ionization Quadrupole Time-of-flight Mass Spectrometry: Profiles in Healthy Adults
Protein & Peptide Letters Kidney Dysfunction is Associated with a High Burden of Cerebral Small Vessel Disease in Primary Intracerebral Hemorrhage
Current Neurovascular Research Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients
Current Aging Science Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Retraction Notice to Role of Vitamin K2 in the Treatment of Postmenopausal Osteoporosis
Current Drug Safety Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis
Current Medicinal Chemistry The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Renin-Angiotensin System and Alzheimer’s Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives
Protein & Peptide Letters Gene and Cell Therapy for Prion Diseases
Infectious Disorders - Drug Targets